NCT05741112 The Long COVID-19 Wearable Device Study
| NCT ID | NCT05741112 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Scripps Translational Science Institute |
| Condition | Long COVID |
| Study Type | INTERVENTIONAL |
| Enrollment | 100,500 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100,500 participants in total. It began in 2023-11-16 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.
Eligibility Criteria
Inclusion Criteria: * Is at least 18 years old. * Has a self/and or physician diagnosis of: * Long COVID (based on the WHO working definition), * ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome, self-diagnosis based on IOM criteria), and/or * POTS (Postural Orthostatic Tachycardia Syndrome). * Is interested in tools to manage ME/CFS, POTS, and/or Long COVID symptoms. * Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one. * Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly. * Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback. * Agrees to disclose involvement in other ME/CFS, POTS, and/or Long COVID interventions such as medical treatment, self-management, and other interventional studies. * Agrees to complete at least 75% of the study surveys. Exclusion Criteria: * As long as they meet inclusion there is no exclusion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05741112 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Long COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05741112 currently recruiting?
Yes, NCT05741112 is actively recruiting participants. Contact the research team at agoosen@scripps.edu for enrollment information.
Where is the NCT05741112 trial being conducted?
This trial is being conducted at La Jolla, United States.
Who is sponsoring the NCT05741112 clinical trial?
NCT05741112 is sponsored by Scripps Translational Science Institute. The trial plans to enroll 100,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.